Journal of Business Thought

Open Access Open Access  Restricted Access Subscription Access

Role of Medical Representatives in Influencing Medicine Prescription Behaviour of Doctors


Affiliations
1 Department of Commerce, Delhi School of Economics, University Enclave, Delhi – 110007, India
 

Medicine Prescription Behaviour (MPB) is a doctor’s decision for a specific drug/medicine of a pharmaceutical company. Doctors consider several factors in their evaluation process while selecting a particular drug. The transfer of information to doctors, especially through detailing by Medical Representatives (MRs), is a crucial element of pharmaceutical marketing. New drugs are introduced in the market very frequently because of rapid change in preferences and prescription patterns of doctors. Therefore, understanding shift in doctors’ desires regarding selection of a particular drug give opportunities to proactive pharmaceutical companies to increase their market share by timely anticipating doctors' preferences. This paper seeks to identify the influence of level of knowledge, kind of information, communication skills and frequent visit of MRs on three aspects of MPB; early prescription of new drugs, cost of drugs and habitual aspect. Testable hypotheses were developed with respect to MPB and a survey questionnaire was designed to capture data from 150 doctors practicing in Delhi. The hypotheses were tested using Multiple Regression and Analysis of Variance (ANOVA). The study concluded that the knowledge, kind of information, communication skills and professionalism factor of MRs influence doctors towards early prescription of new drugs and their habitual behaviour towards prescription of drugs. The study concluded that knowledge and the kind of information given by MRs are significant predictors of cost aspect of MPB of doctors.

Keywords

Drugs, Medical Representatives, Medicine Prescription Behaviour, Pharmaceutical Marketing.
User
Notifications
Font Size

  • Abdelaziz AB, Harrabi I, Rahmani S. Attitudes of general practitioners to pharmaceutical sales representatives in Sousse. East Mediterranean Health J. 2003; 9(5-6):1075–8.

  • Accenture. Physicians seek more detailed, comparative and customized information from pharmaceutical representatives. Retrieved September 16 2003. accen-ture.com/xd/xd.asp?it=enweb&xd=_dyndynamicpressrelease_630.xml

  • Alkhateeb FM, Khanfar NM, Clauson KA. Characteristics of physicians who frequently see pharmaceutical sales representatives. J Hosp Mark Public Relations. 2009; 19(1):2–14. PMid: 19197653. https://doi.org/10.1080/15390940802581374

  • Allan GM, Innes G. Do family doctors know the costs of medical care. Can Fam Phys. 2004; 50:263–70.

  • Allan GM, Innes G. Family practice residents’ awareness of medical care costs in British Columbia. Fam Med. 2002; 34:106–1.

  • Arora, Usha, Taneja, Girish. An analytical study of doctors behaviour towards marketing of pharmaceutical products. Indian Journal of Marketing. 2006;36 (11):10-13.

  • Bednarik J. Does brand differentiate pharmaceuticals?Neuro Endocrinol Lett. 2005; 26(6):635–2.

  • Berndt ER, Bui LT, Reiley DH, Urban GL. The roles of marketing, product quality and price competition in the growth and composition of the US antiulcer industry. The Economics of New Goods. Chicago: University of Chicago Press; 1997.

  • Bourke J, Roper S. In with the new: the determinants of prescribing innovation by general practitioners in Ireland. Eur J Health Econ. 2012; 13:393–07. doi: 10.1007/s10198011-0311-5. PMid: 21503785. https://doi.org/10.1007/s10198-011-0311-5

  • Bulte C, Lilien G. Medical innovation revisited: social contagion versus marketing effort. Am J Sociol. 2001; 106:1409–35.doi: 10.1086/320819 https://doi.org/10.1086/320819

  • Caudill T, Johnson M, Rich E, McKinney W. Doctors, pharmaceutical representatives and the cost of prescribing. Arch Fam Med. 1996; 5(4):201–6. PMid: 8769907. https://doi.org/10.1001/archfami.5.4.201

  • Coleman JS, Elihu K, Herbert M. Medical Innovation: A Diffusion Study. Indianapolis: The Bobbs-Merrill Company; 1966.

  • Corrigan M, Glass H. Physician participation in clinical studies and subsequent prescribing of new drugs. P&T.2005; 30:60–6.

  • Cosceilli A, Shum M. An empirical model of learning andpatient spillovers in new drug entry. J. Econom. 2004; 122:213–46. https://doi.org/10.1016/j.jeconom.2003.09.002

  • Doney PM, Cannon JP. An examination of the nature of trust in buyer-seller relationships. J. Mark. 1997; 61:35–51. https://doi.org/10.2307/1251829 https://doi.org/10.1177/002224299706100203

  • Dybdahl T, Søndergaard J, Kragstrup J, Kristiansen I, Andersen M. Primary care physicians’ adoption of new drugs is not associated with their clinical interests:a pharmacoepidemiologic study. Scand J Prim Health Care. 2011; 29:117–21. PMid: 21510719 PMCid: PMC3347948. doi: 10.3109/02813432.2011.570024 https://doi.org/10.3109/02813432.2011.570024

  • Edwards I, Jones M, Higgs JG. What is collaborative reasoning? Advances in Physiotherapy. 2004; 6:70–83. https:// doi.org/10.1080/14038190410018938

  • Garjon F, Azparren A, Vergara I, Azaola B, Loayssa J.Adoption of new drugs by physicians: a survival analysis. BMC Health Serv Res. 2012; 12:56. PMid: 22401169PMCid: PMC3353238 doi: 10.1186/1472-6963-12-56https://doi.org/10.1186/1472-6963-12-56

  • Glass H, Dalton D. Profiles of phase IV investigators and subsequent prescribing of the study drug. J Pharm Mark Manage. 2006; 17:3–17. doi: 10.3109/J058v17n03_02 https://doi.org/10.3109/J058v17n03_02

  • Glass HE, Rosenthal B. Demographics, practices, and prescribing characteristics of doctors who are early adopters of new drugs. Pharmacy and Therapeutics. 2004; 29(1):699– 708.

  • Glass H, Rosenthal B. Post-launch clinical investigator drug prescribing in the US. Int J Pharm Med. 2005; 19:97–104. doi: 10.2165/00124363-200519020-00005 https://doi.org/10.2165/00124363-200519020-00005

  • Gonul FF, Carter F, Petrova E, Srinivasan K. Promotion of prescription drugs and its impact on doctors’ choice behavior. J. Mark. 2001; 65:79–90. https://doi.org/10.1509/jmkg.65.3.79.18329

  • Grone O, Garcia-Barbero M. Trends in integrated care - reflections on conceptual issues. World Health Organization: Copenhagen; EUR/02/5037864. 2002.

  • Groves K, Schellinck T, Sketris I, MacKinnon N. Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2 s) in Nova Scotia, Canada: considerations for targeted academic detailing. Res Social Adm Pharm. 2010; 6:257–67. PMid: 20813338. doi: 10.1016/j.sapharm.2 https://doi.org/10.1016/j.sapharm.2009.09.003

  • Hart J, Salman H, Bergman M, Neuman V, Rudniki C, et al. Do drug costs affect physicians’ prescription decisions?J Intern Med. 1997; 241:415–20. https://doi.org/10.1046/j.1365-2796.1997.137143000.x

  • Hartzema AG, Christensen DB. Nonmedical factors associated with the prescribing volume among family practitioners in an HMO. Medical Care. 1983; 21:990–1000. https://doi.org/10.1097/00005650-198310000-0000537.

  • Health Strategies Group, Inc. Pharma SFE. 2003. www.healthstrategies.com/products/sfe_reports.html

  • Henry J. National Survey of Doctors: Doctors and Prescription Drugs. Kaiser Family Foundation. 2002.

  • Huskamp H, O’Malley A, Horvitz-Lennon M, Taub A, Berndt ER, Donohue J. How quickly do physicians adopt new drugs? The case of second-generation anti-psychotics. Psychiatr Serv. 2013; 64:324–0. PMid: 23280376 PMCid: PMC3907700. doi: 10.1176/appi.ps.201200186 https://doi.org/10.1176/appi.ps.201200186

  • IMS Health. IMS forecasts global pharmaceutical market growth of 4-6% in 2010; predicts 4-7% expansion through 2013. Retrieved March 16, 2010. www.imshealth.com: http://www.imshealth.com

  • Janakiraman R, Dutta S, Sismeiro C, Stern P. Doctors ‘ persistence and its implications for their response to promotion of prescription drugs. Management Science. 2008;54(6):1080– 3. https://doi.org/10.1287/mnsc.1070.0799

  • John AH. Effects of an educational intervention on residents’ knowledge and attitudes toward interactions with pharmaceutical representatives. Gen Internal Med. 1997; 12(10):639–2. PMid: 9346461 PMCid: PMC1497177. https://doi.org/10.1046/j.1525-1497.1997.07126.x

  • Kasliwal N. “A study of psychosocial factors on doctors prescribing behavior - An Empirical Study in India.Journal of Business and Management. 2013; 13(2):5–0.e-ISSN: 2278-487X, p-ISSN: 2319-7668. https:// doi. org/10.9790/487X-1320510

  • Kotwani A, Wattal C, Katewa S, Joshi P, Holloway K. Factors influencing primary care physicians to prescribe antibiotics in Delhi India. Family Practice. 2010; 27:684–0. PMid: 20660529. https://doi.org/10.1093/fampra/cmq059

  • Laroche M, Bergeron J, Goutaland C. How intangibility affects perceived risk: the moderating role of knowledge and involvement. Journal of Services Marketing. 2003; 17(2):122–0. https://doi.org/10.1108/08876040310467907

  • Layton RM, Sritanyarat W, Chadbunchachai S. Sources of information for new drugs among doctors in Thailand . Pharm World Science. 2007; 29(6):619–7. PMid: 17710562. https://doi.org/10.1007/s11096-007-9112-4

  • Lin S, Jan K, Kao J. Colleague interactions and new drug prescribing behavior: the case of the initial prescription of antidepressants in Taiwanese medical centers. Soc Sci Med. 2011; 73:1208–3. PMid: 21962150. doi: 10.1016/j.socscimed.2011.06.065. https://doi.org/10.1016/j.socs-cimed.2011.06.065

  • Lurie N, Rich E, Simpson D. Pharmaceutical representatives in academic medical centers. J Gen Intern Med.1990; 5:240– 4. PMid: 2341925. https://doi.org/10.1007/BF02600542

  • McGettigan P, Golden J, Fryer J, Chan R, Feely J. Prescribers prefer people: the sources of information used by doctors for prescribing suggest that the medium is more important than the message. Brit J Clin Pharmacol. 2001; 51(2):184– 9. PMid: 11259994 PMCid: PMC2014444. https://doi.org/10.1111/j.1365-2125.2001.01332.x

  • Mckinney WP. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA 1693. 1990;264(13):1693–. PMid: 2398609. https://doi.org/10.1001/jama.1990.03450130065028

  • Mizik N, Jacobson R. Are doctors’ easy marks? Quantifying the effects of detailing and sampling on new prescriptions. Management Science. 2004; 50(12):1704–5. https://doi.org/10.1287/mnsc.1040.0281

  • Narayanan S, Manchanda P, Pradeep. Temporal differences in the role of marketing communication in new products categories. J Mark Res. 2005 Aug; 42:278–0. https://doi.org/10.1509/jmkr.2005.42.3.278

  • Norris P, Herxheimerl A, Lexchin J, Mansfield P. Drug Promotion: What we know, what we have yet to learn. World Health Organization; 2004. p. 11.

  • Peay M, Peay E. Innovation in high risk drug therapy. Soc Sci Med. 1994; 39:39–2. doi: 10.1016/0277-9536(94)90164-3 https://doi.org/10.1016/0277-9536(94)90164-3

  • Prosser H, Walley T. A qualitative study of GP’s and PCO stakeholders’ views on the importance and influence of cost on prescribing. Soc Sci Med. 2005; 60:1335–6. PMid: 15626528. https://doi.org/10.1016/j.socscimed.2004.07.013

  • Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs - the importance of who says what. Family Practice. 2003; 20:61–. PMid: 12509373.https://doi.org/10.1093/fampra/20.1.61

  • Prounis C. Successful sales management. What doctors want? Pharmaceutical Executive Suppl. 2003. p. 12–9

  • Rajan TD. Getting into the doctor’s mind. Express Pulse.2006; 4.

  • Sahad PV, Sharma EK. The long term prescription. Business Today; 2005 Dec. p. 138.

  • Scott J. Docs want to hear from knowledgeable reps. 2003 Aug. pharm-rep.adv100.com/pharmrep/article/articleDetail.jsp?id=118400

  • Higgins SP. Drug representatives: giving you lunch or stealing your soul? Dermatology Online J. 2007; 13(4):5.

  • Taneja G. Impact of pharmaceutical industry promotion mix on doctors prescribing behaviour. Asia-Pacific Business Review. 2008; 4:13–. https://doi.org/10.1177/097324700800400408

  • Theodorou M, Tsiantou VV, Pavlakis A. Factors influencing prescribing behaviour of doctors in Greece andCyprus: results from a questionnaire based survey”. BMC Health Serv Res. 2009; 9:2–. PMid: 19695079 PMCid: PMC2737540. https://doi.org/10.1186/1472-6963-9-150

  • Wazana A. Doctors and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000; 283(3):373–0. https://doi.org/10.1001/jama.283.3.373

  • Wright RF, Lundstrom WJ. Doctors’ perceptions of pharmaceutical sales representatives: a model for analyzing the customer relationship. Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing. 2004; 4(1):29–8. https://doi.org/10.1057/palgrave.jmm.5040140

  • Ziegler MG, Lew P, Singer CB. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995; 273:1296–. https://doi.org/10.1001/jama.1995.03520400066047


Abstract Views: 323

PDF Views: 287




  • Role of Medical Representatives in Influencing Medicine Prescription Behaviour of Doctors

Abstract Views: 323  |  PDF Views: 287

Authors

Kiran Bala
Department of Commerce, Delhi School of Economics, University Enclave, Delhi – 110007, India
Kavita Sharma
Department of Commerce, Delhi School of Economics, University Enclave, Delhi – 110007, India

Abstract


Medicine Prescription Behaviour (MPB) is a doctor’s decision for a specific drug/medicine of a pharmaceutical company. Doctors consider several factors in their evaluation process while selecting a particular drug. The transfer of information to doctors, especially through detailing by Medical Representatives (MRs), is a crucial element of pharmaceutical marketing. New drugs are introduced in the market very frequently because of rapid change in preferences and prescription patterns of doctors. Therefore, understanding shift in doctors’ desires regarding selection of a particular drug give opportunities to proactive pharmaceutical companies to increase their market share by timely anticipating doctors' preferences. This paper seeks to identify the influence of level of knowledge, kind of information, communication skills and frequent visit of MRs on three aspects of MPB; early prescription of new drugs, cost of drugs and habitual aspect. Testable hypotheses were developed with respect to MPB and a survey questionnaire was designed to capture data from 150 doctors practicing in Delhi. The hypotheses were tested using Multiple Regression and Analysis of Variance (ANOVA). The study concluded that the knowledge, kind of information, communication skills and professionalism factor of MRs influence doctors towards early prescription of new drugs and their habitual behaviour towards prescription of drugs. The study concluded that knowledge and the kind of information given by MRs are significant predictors of cost aspect of MPB of doctors.

Keywords


Drugs, Medical Representatives, Medicine Prescription Behaviour, Pharmaceutical Marketing.

References





DOI: https://doi.org/10.18311/jbt%2F2019%2F23767